Original news and analysis on international IP policy
By Tatum Anderson for Intellectual Property Watch Indian generic manufacturers may be allowed to export a cheaper HIV/AIDS treatment to middle-income countries if US pharmaceutical company Gilead fails to win a patent for the drug in India. And a turnaround…
By Itaru Nitta, Green Intellectual Property Project, Geneva, Switzerland Since the current IP framework has been shaped in wealthy societies of the North, accompanied by fertile markets, the North is required to rebuild the framework if they attempt to expand…
Por Claudia Jurberg para Intellectual Property Watch RÍO DE JANEIRO – Hace poco, el Tribunal Supremo de Brasil aprobó, por un margen estrecho de 6 a 5, la investigación sobre células madre embrionarias, luego de analizar el tema durante tres…
Note: the final decisions of convention on biological diversity governing body are available here.
A decision on a way forward on a global access and benefit-sharing regime was reached at a meeting of the parties to the Convention on Biological Diversity from 19 to 30 May in Bonn.
The main body of the document describes steps needed to reach international consensus on the content of such a regime. Annex I of the document sets out a draft text for the international regime, and annex II contains terms of reference for expert technical and legal groups whose creation is mandated by the main text.
By Claudia Jurberg for Intellectual Property Watch RIO DE JANEIRO – After three days of consideration, the Brazilian Supreme Court last week approved by a narrow 6 to 5 margin research involving embryonic stem cells. The 29 May vote followed…
By Claudia Jurberg for Intellectual Property Watch The Brazilian government recently declared the drug Tenofovir, used against HIV/AIDS, to be of public interest. The announcement signals the country’s interest in using an option to avoid the patent on the drug…
By Catherine Saez After an innovative partnership between a non-governmental group and a pharmaceutical company led to a new cheap non-patented drug against malaria being available in Africa in 2007, the model is being implemented again with another new non-patented…
By Claudia Jurberg for Intellectual Property Watch RIO DE JANEIRO – After 10 years of debate, Brazil approved in February the commercialisation of two varieties of genetically modified corn, a highly contentious decision in the country that has become linked…
Par Kaitlin Mara et William New Un groupe d’experts gouvernementaux et non gouvernementaux a souligné, la semaine dernière, les conséquences importantes que les négociations menées par les principales économies en vue de conclure des accords de libre-échange bilatéraux ont sur…
Por Kaitlin Mara y William New Un panel integrado por expertos en cuestiones de propiedad intelectual y biodiversidad gubernamentales y no gubernamentales destacó la semana pasada el gran impacto que tienen las negociaciones comerciales bilaterales de las principales economías del…